51ÂÜÀò PHARMA ANNOUNCES MOVE TO NEW CORPORATE HEADQUARTERS
Lyon, France., October 3rd, 2019 – 51ÂÜÀò, a private clinical stage biotechnology company developing innovative drug candidates, today announced the relocation of the Company’s headquarters to the 8th Arrondissement in Lyon in the BIOSERRA buildings at 60 avenue Rockefeller, to support long-term growth and advancement of pipeline.
Read next in 'Press releases'
- 51ÂÜÀò appoints Jeff George as Chairman to support next phase to growth and Phase 3 readiness
- 51ÂÜÀò nomme Jeff George Président du Conseil d’Administration pour soutenir sa prochaine phase de croissance et la préparation à la Phase 3
- 51ÂÜÀò announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 51ÂÜÀò annonce l’obtention des résultats finaux de l’étude clinique de Phase 2 ALPESTRIA‑1 dans le syndrome d’Alport, confirmant la capacité du vonafexor à inverser la trajectoire du déclin rénal et à démontrer un effet thérapeutique durable
- 51ÂÜÀò annonce la finalisation de son financement de série C avec Vesalius Biocapital et la poursuite de son étude clinique de phase 2 ALPESTRIA-1